Equity Research on Sequenom Inc. and Biogen Idec Inc. -- Biotechnology Industry Taking the Good With the Bad
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 07/06/12 -- has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Biotechnology industry and are offering free analytical research on (NASDAQ: SQNM) and (NASDAQ: BIIB). Register with us now to have free access to these research reports. Simply click on the link below.
Companies in the biotechnology industry, such as Sequenom Inc. and Biogen Idec Inc. have been facing both positive and negative trends over the last little while. One major challenge over the past few years has been the huge patent cliff which has seen a large number of lucrative patents expiring. Many industry players have been struggling with shrinking revenue streams as new products are not anticipated to bring in revenues of the same magnitude. Get your free reports on and at . There is no commitment to join.
ShinesRooms.com is the Ultimate Trading Environment for investors. If you are considering owning Sequenom Inc. and Biogen Idec Inc. then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing.
Companies have been investing heavily in research and development in recent years but as time marches on, many are looking to partnerships, mergers and acquisitions as a way to access new products with lower investment in research and development. Biogen Idec is a good example of the aforementioned trend as it recently announced that it has entered into an exclusive worldwide option and collaboration agreement with Isis Pharmaceuticals Inc. to develop and commercialize a treatment for Steinert disease. report is accessible for free by registering today at
On the plus side, evolving health challenges and increasing wealth in emerging markets continue to boost demand for new therapeutics and vaccines. As a result the Biotechnology industry has largely been outpacing other markets despite continued macroeconomic volatility. report is accessible for free by registering today at
The two stocks research reports are available for free by signing up now on the link below.
Shine's Rooms is the brainchild of David Shine, a 13-year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting-edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.
To view our visit this link .
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.07.2012 - 12:00 Uhr
Sprache: Deutsch
News-ID 162846
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 174 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Equity Research on Sequenom Inc. and Biogen Idec Inc. -- Biotechnology Industry Taking the Good With the Bad"
steht unter der journalistisch-redaktionellen Verantwortung von
Shinesrooms.com (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
